L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms

Ali Reza Serati, Mohammad Reza Motamedi, Sepideh Emami, Peyman Varedi, Mohammad R Movahed

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objectives: L-Carnitine is a crucial component of activated fatty acid transport. The aim of this study was to evaluate the effect of L-carnitine on patients with a history of mild heart failure and diastolic dysfunction. Methods: Twenty-nine patients with a history of NYHA functional class II symptoms and ejection fraction >45% with documented grade 1 diastolic dysfunction on echocardiogram were randomized in blinded fashion to receive 1,500 mg of L-carnitine daily for 3 months in comparison to a no treatment group (31 patients). Baseline echocardiographic and follow-up measurements of diastolic parameters were assessed after 3 months. Results: Important parameters of diastolic function improved in the L-carnitine group only: left atrial size (3.6 ± 0.4 cm before treatment vs. 3.4 ± 0.5 cm after treatment, p = 0.01); isovolemic relaxation time (127 ± 26 ms before vs. 113 ± 24 ms after treatment, p = 0.007); septal mitral E' velocity (0.064 ± 0.01 m/s before vs. 0.074 ± 0.01 m/s after treatment, p = 0.01), and lateral mitral E velocity (0.082 ± 0.01 m/s before vs. 0.091 ± 0.02 m/s after treatment, p = 0.006). Dyspnea also significantly improved in L-carnitine-treated patients. Conclusion: In patients with a history of diastolic heart failure, important indices of diastolic function and symptoms appear to improve with L-carnitine treatment.

Original languageEnglish (US)
Pages (from-to)178-182
Number of pages5
JournalCardiology
Volume116
Issue number3
DOIs
StatePublished - Aug 2010

Fingerprint

Diastolic Heart Failure
Carnitine
Therapeutics
Dyspnea
Fatty Acids

Keywords

  • Antioxidant
  • Carnitine
  • Diastolic
  • Diastolic function
  • Diastology
  • Echocardiography
  • Heart failure
  • L-Carnitine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. / Serati, Ali Reza; Motamedi, Mohammad Reza; Emami, Sepideh; Varedi, Peyman; Movahed, Mohammad R.

In: Cardiology, Vol. 116, No. 3, 08.2010, p. 178-182.

Research output: Contribution to journalArticle

Serati, Ali Reza ; Motamedi, Mohammad Reza ; Emami, Sepideh ; Varedi, Peyman ; Movahed, Mohammad R. / L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. In: Cardiology. 2010 ; Vol. 116, No. 3. pp. 178-182.
@article{3c1f3eb8e2364a4ba47dfa264f946300,
title = "L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms",
abstract = "Objectives: L-Carnitine is a crucial component of activated fatty acid transport. The aim of this study was to evaluate the effect of L-carnitine on patients with a history of mild heart failure and diastolic dysfunction. Methods: Twenty-nine patients with a history of NYHA functional class II symptoms and ejection fraction >45{\%} with documented grade 1 diastolic dysfunction on echocardiogram were randomized in blinded fashion to receive 1,500 mg of L-carnitine daily for 3 months in comparison to a no treatment group (31 patients). Baseline echocardiographic and follow-up measurements of diastolic parameters were assessed after 3 months. Results: Important parameters of diastolic function improved in the L-carnitine group only: left atrial size (3.6 ± 0.4 cm before treatment vs. 3.4 ± 0.5 cm after treatment, p = 0.01); isovolemic relaxation time (127 ± 26 ms before vs. 113 ± 24 ms after treatment, p = 0.007); septal mitral E' velocity (0.064 ± 0.01 m/s before vs. 0.074 ± 0.01 m/s after treatment, p = 0.01), and lateral mitral E velocity (0.082 ± 0.01 m/s before vs. 0.091 ± 0.02 m/s after treatment, p = 0.006). Dyspnea also significantly improved in L-carnitine-treated patients. Conclusion: In patients with a history of diastolic heart failure, important indices of diastolic function and symptoms appear to improve with L-carnitine treatment.",
keywords = "Antioxidant, Carnitine, Diastolic, Diastolic function, Diastology, Echocardiography, Heart failure, L-Carnitine",
author = "Serati, {Ali Reza} and Motamedi, {Mohammad Reza} and Sepideh Emami and Peyman Varedi and Movahed, {Mohammad R}",
year = "2010",
month = "8",
doi = "10.1159/000318810",
language = "English (US)",
volume = "116",
pages = "178--182",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms

AU - Serati, Ali Reza

AU - Motamedi, Mohammad Reza

AU - Emami, Sepideh

AU - Varedi, Peyman

AU - Movahed, Mohammad R

PY - 2010/8

Y1 - 2010/8

N2 - Objectives: L-Carnitine is a crucial component of activated fatty acid transport. The aim of this study was to evaluate the effect of L-carnitine on patients with a history of mild heart failure and diastolic dysfunction. Methods: Twenty-nine patients with a history of NYHA functional class II symptoms and ejection fraction >45% with documented grade 1 diastolic dysfunction on echocardiogram were randomized in blinded fashion to receive 1,500 mg of L-carnitine daily for 3 months in comparison to a no treatment group (31 patients). Baseline echocardiographic and follow-up measurements of diastolic parameters were assessed after 3 months. Results: Important parameters of diastolic function improved in the L-carnitine group only: left atrial size (3.6 ± 0.4 cm before treatment vs. 3.4 ± 0.5 cm after treatment, p = 0.01); isovolemic relaxation time (127 ± 26 ms before vs. 113 ± 24 ms after treatment, p = 0.007); septal mitral E' velocity (0.064 ± 0.01 m/s before vs. 0.074 ± 0.01 m/s after treatment, p = 0.01), and lateral mitral E velocity (0.082 ± 0.01 m/s before vs. 0.091 ± 0.02 m/s after treatment, p = 0.006). Dyspnea also significantly improved in L-carnitine-treated patients. Conclusion: In patients with a history of diastolic heart failure, important indices of diastolic function and symptoms appear to improve with L-carnitine treatment.

AB - Objectives: L-Carnitine is a crucial component of activated fatty acid transport. The aim of this study was to evaluate the effect of L-carnitine on patients with a history of mild heart failure and diastolic dysfunction. Methods: Twenty-nine patients with a history of NYHA functional class II symptoms and ejection fraction >45% with documented grade 1 diastolic dysfunction on echocardiogram were randomized in blinded fashion to receive 1,500 mg of L-carnitine daily for 3 months in comparison to a no treatment group (31 patients). Baseline echocardiographic and follow-up measurements of diastolic parameters were assessed after 3 months. Results: Important parameters of diastolic function improved in the L-carnitine group only: left atrial size (3.6 ± 0.4 cm before treatment vs. 3.4 ± 0.5 cm after treatment, p = 0.01); isovolemic relaxation time (127 ± 26 ms before vs. 113 ± 24 ms after treatment, p = 0.007); septal mitral E' velocity (0.064 ± 0.01 m/s before vs. 0.074 ± 0.01 m/s after treatment, p = 0.01), and lateral mitral E velocity (0.082 ± 0.01 m/s before vs. 0.091 ± 0.02 m/s after treatment, p = 0.006). Dyspnea also significantly improved in L-carnitine-treated patients. Conclusion: In patients with a history of diastolic heart failure, important indices of diastolic function and symptoms appear to improve with L-carnitine treatment.

KW - Antioxidant

KW - Carnitine

KW - Diastolic

KW - Diastolic function

KW - Diastology

KW - Echocardiography

KW - Heart failure

KW - L-Carnitine

UR - http://www.scopus.com/inward/record.url?scp=77954562244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954562244&partnerID=8YFLogxK

U2 - 10.1159/000318810

DO - 10.1159/000318810

M3 - Article

C2 - 20639632

AN - SCOPUS:77954562244

VL - 116

SP - 178

EP - 182

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 3

ER -